MT Højgaard Holding A/S: MT Højgaard Danmark wins tender from Copenhagen Airport
MT Højgaard Holding’s business unit MT Højgaard Danmark has won the first phase of Copenhagen Airport’s tender for…
Novo Nordisk’s Oral Wegovy Wins EU Approval, but a Strict Dosing Regimen and Mounting Rivalry Chec
The European Commission’s green light for Novo Nordisk’s oral Wegovy tablet on 15 July 2026 marks the first…
Novo Nordisk’s Oral Wegovy Wins EU Approval – So Why Isn’t the Market Celebrating?
Novo Nordisk finally has what it has been fighting for: European regulators have cleared the oral version of…
Novo Nordisk’s Oral Wegovy Wins EU Nod: Can the Pill’s US Success Scale Across 27 Markets?
For millions of Europeans who have shunned weight-loss injections, the arrival of a daily pill could change the…
Wegovy Pill Wins EU Approval, Yet Novo Nordisk’s Rally Faces a Jittery Wait for FDA and Earnings
The European Commission has handed Novo Nordisk a clear edge in the race to dominate the oral weight?loss…
Novo Nordisk Puts 5 Billion DKK Behind Its Stock as Pipeline Wins Offset Cyber Setback
The Danish pharmaceutical giant has endured a week of stark contrasts, threading clinical breakthroughs, a regulatory milestone, and…
Novo Nordisk’s Contradictory Landscape: Oral Wegovy Wins a Second Market as US Headwinds Intensify
Novo Nordisk’s oral Wegovy gets UAE approval, but US pricing pressure mounts as CVS adds Lilly’s Foundayo; stock…
Novo Nordisk’s Pipeline Crossroads: CagriSema, Zenagamtide and EU Wins Put Stock Under the Microsc
Novo Nordisk unveils CagriSema Phase 3 data (1.91% HbA1c drop, 14.2% weight loss) and Zenagamtide Phase 2 at…
Solintel Wins Tallinnovation Award to Deploy Energy-Independent Smart Bus Stops in Tallinn
Solintel Solintel OÜ, the Tallinn-based developer of autonomous smart city infrastructure — the top funding tier — in…
Oral Wegovy Wins EMA Panel Backing, Yet Novo Nordisk Shares Remain Under Pressure
EMA recommends first oral GLP-1 obesity pill for EU approval, but Novo Nordisk shares tumble 15% YTD amid…
Novo Nordisk’s Oral Wegovy Wins Patient Preference as Long-Term Efficacy Data Strengthens Case
84% of patients prefer Novo Nordisk’s oral Wegovy over Lilly’s pill, with 14x lower dropout rate. Phase 3…
Generics, Pipeline Wins, and a Pivotal Earnings Report
Novo Nordisk enters a pivotal week with Canada approving first Ozempic generics, oral Ozempic exceeding prescription expectations, and…